Literature DB >> 21537181

MMP-9 and the perioperative management of LASIK surgery.

Robert Sambursky1, Terrence P O'Brien.   

Abstract

PURPOSE OF REVIEW: Hyperosmolarity is a central mechanism causing ocular surface inflammation and eye irritation in typical patients suffering from tear dysfunction. Tear composition in dry eyes, or dysfunctional tear syndrome, may destabilize the tear film and cause ocular surface epithelial disease. Increased activity of matrix metalloproteinases (MMPs), especially MMP-9, plays a critical role in wound healing and inflammation and is primarily responsible for the pathologic alterations to the ocular surface that leads to a dysfunctional tear state. RECENT
FINDINGS: Altered corneal epithelial barrier function is the cause for ocular irritation and visual morbidity in dry eye disease. The increased MMP-9 activity in dry eyes may contribute to deranged corneal epithelial barrier function, increased corneal epithelial desquamation, and corneal surface irregularity.
SUMMARY: Dry eye is one of the most common complications of photorefractive keratectomy and laser in-situ keratomileusis (LASIK). LASIK has both a neurotrophic effect on the cornea and leads to a physical change in corneal shape that results in a change in tear dynamics, leading to ocular surface desiccation. The reduction in tear function after LASIK may induce an increase in osmolarity and consequently raise the concentration of proinflammatory cytokines and MMP-9 in the tear film, which results in dry eyes and insufficient attachment between the corneal flap and the corneal bed. Appropriate diagnosis and management of dysfunctional tear syndrome may lead to less postoperative LASIK complications.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21537181     DOI: 10.1097/ICU.0b013e32834787bb

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  9 in total

1.  Short-term effects of overnight orthokeratology on corneal epithelial permeability and biomechanical properties.

Authors:  Thao N Yeh; Harry M Green; Yixiu Zhou; Julie Pitts; Britney Kitamata-Wong; Sophia Lee; Shiyin L Wang; Meng C Lin
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-06-06       Impact factor: 4.799

Review 2.  The Matrix Metalloproteinase 9 Point-of-Care Test in Dry Eye.

Authors:  Nicole L Lanza; Felipe Valenzuela; Victor L Perez; Anat Galor
Journal:  Ocul Surf       Date:  2016-02-02       Impact factor: 5.033

Review 3.  Matrix metalloproteinases in diabetic retinopathy: potential role of MMP-9.

Authors:  Renu A Kowluru; Qing Zhong; Julia M Santos
Journal:  Expert Opin Investig Drugs       Date:  2012-04-23       Impact factor: 6.206

4.  Dry Eye Profiles in Patients with a Positive Elevated Surface Matrix Metalloproteinase 9 Point-of-Care Test Versus Negative Patients.

Authors:  Nicole L Lanza; Allison L McClellan; Hatim Batawi; Elizabeth R Felix; Konstantinos D Sarantopoulos; Roy C Levitt; Anat Galor
Journal:  Ocul Surf       Date:  2016-01-22       Impact factor: 5.033

5.  Inhibition by female sex hormones of collagen degradation by corneal fibroblasts.

Authors:  Hongyan Zhou; Kazuhiro Kimura; Tomoko Orita; Teruo Nishida; Koh-Hei Sonoda
Journal:  Mol Vis       Date:  2011-12-27       Impact factor: 2.367

Review 6.  Impact of corneal refractive surgery on the precorneal tear film.

Authors:  Bhavana Sharma; Deepak Soni; Harsha Saxena; Louis J Stevenson; Samendra Karkhur; Brijesh Takkar; Rasik B Vajpayee
Journal:  Indian J Ophthalmol       Date:  2020-12       Impact factor: 1.848

Review 7.  The Role of Endogenous Antimicrobial Peptides in Modulating Innate Immunity of the Ocular Surface in Dry Eye Diseases.

Authors:  Youssof Eshac; Rachel L Redfern; Vinay Kumar Aakalu
Journal:  Int J Mol Sci       Date:  2021-01-13       Impact factor: 5.923

8.  Recent developments on dry eye disease treatment compounds.

Authors:  Basilio Colligris; Hanan Awad Alkozi; Jesus Pintor
Journal:  Saudi J Ophthalmol       Date:  2013-12-14

Review 9.  Dry Eye Post-Laser-Assisted In Situ Keratomileusis: Major Review and Latest Updates.

Authors:  Eyal Cohen; Oriel Spierer
Journal:  J Ophthalmol       Date:  2018-01-28       Impact factor: 1.909

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.